Press Releases 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Market Closed - Nasdaq Other stock markets 02:00:00 15/06/2024 am IST			5-day change	1st Jan Change
0.2731 ^USD	-3.09%		-22.19%	-73.23%

30/05	60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	CI
20/05	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis	11/06	AQ
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	30/05	AQ
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20/05	AQ
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	15/05	AQ
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	08/05	AQ
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02/05	AQ
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	03/04	AQ
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14/03	AQ
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	20/02	AQ
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	08/02	AQ
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	31/01	PR
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering	31/01	AQ
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	30/01	PR
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering	30/01	AQ
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting	22/01	AQ
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements	16/01	AQ
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024	26/12	AQ
Thinking about buying stock in Sportsmap Tech Acquisition, Dune Acquisition, Macy's, Cybin, or 60 Degrees Pharmaceuticals?	21/12	PR
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease	15/11	AQ
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston	19/23/19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Press Releases

Filters